ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford bought 16,907 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average cost of $1.83 per share, for a total transaction of $30,939.81. Following the completion of the transaction, the director now directly owns 43,418 shares in the company, valued at approximately $79,454.94. This trade represents a 63.77 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Michael Swinford also recently made the following trade(s):
- On Wednesday, November 20th, Michael Swinford bought 16,471 shares of ReWalk Robotics stock. The stock was purchased at an average cost of $1.84 per share, for a total transaction of $30,306.64.
ReWalk Robotics Price Performance
NASDAQ:LFWD opened at $2.06 on Wednesday. The business’s 50-day moving average is $2.56 and its two-hundred day moving average is $3.50. ReWalk Robotics Ltd. has a 12 month low of $1.70 and a 12 month high of $9.10.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of ReWalk Robotics in a research report on Wednesday, November 13th.
Get Our Latest Stock Analysis on ReWalk Robotics
Institutional Trading of ReWalk Robotics
An institutional investor recently bought a new position in ReWalk Robotics stock. Dimensional Fund Advisors LP bought a new stake in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned approximately 0.16% of ReWalk Robotics at the end of the most recent reporting period. Institutional investors own 26.76% of the company’s stock.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
See Also
- Five stocks we like better than ReWalk Robotics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Why Invest in High-Yield Dividend Stocks?
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- Transportation Stocks Investing
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.